Current Status and Clinical Application Analysis of PGT-A Genetic Screening Technology in Kyrgyzstan
PGT-A genetic screening technology in Kyrgyzstan is primarily based on NGS next-generation sequencing, covering chromosomal aneuploidy screening. Bishkek reproductive centers can perform blastocyst biopsy + PGT-A, with a screening accuracy of approximately 95-98%, suitable for advanced maternal age, recurrent miscarriage, and recurrent implantation failure. The cost is about 2000-4000 USD/cycle, requiring advance planning for embryo culture and biopsy timing.
Read More